Storia in 1 fonti

LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Maze Therapeutics, Inc. today and set a price target of $57.00.Claim 55% Off Ti...

Raccontata damarkets.businessinsider.com

Timeline cronologica

1. sabato 16 maggio 2026·markets.businessinsider.com
   

   LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)

   LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Maze Therapeutics, Inc. today and set a price target of $57.00.Claim 55% Off Ti...

2. sabato 16 maggio 2026·markets.businessinsider.com
   

   LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

   LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on MoonLake Immunotherapeutics today and set a price target of $33.00.Claim 55% Of...

3. sabato 16 maggio 2026·markets.businessinsider.com
   

   LifeSci Capital Remains a Buy on Perspective Therapeutics (CATX)

   LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Perspective Therapeutics today and set a price target of $15.00.Claim 55% Off...

4. sabato 16 maggio 2026·markets.businessinsider.com
   

   LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)

   In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $24...